```
=> b reg
FILE 'REGISTRY' ENTERED AT 13:04:38 ON 04 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    3 APR 2008  HIGHEST RN 1012038-13-9
DICTIONARY FILE UPDATES:   3 APR 2008  HIGHEST RN 1012038-13-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l17
L11             STR
```




```
VAR G1=O/S
REP G2=(1-3) C
VAR G3=7/9/11
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  16

STEREO ATTRIBUTES: NONE
L13             SCR 1011 OR 1012 OR 1013 OR 1019
L15             SCR 1840
L17       17940 SEA FILE=REGISTRY SSS FUL L11 AND L13 AND L15

100.0% PROCESSED  696595 ITERATIONS                         17940 ANSWERS
SEARCH TIME: 00.00.13


=> d que sta l23
L11             STR
```




```
VAR G1=O/S
REP G2=(1-3) C
VAR G3=7/9/11
```

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L13 SCR 1011 OR 1012 OR 1013 OR 1019
L15 SCR 1840
L17 17940 SEA FILE=REGISTRY SSS FUL L11 AND L13 AND L15
L20 STR







VAR G1=O/S
REP G2=(1-3) C
VAR G3=8/15/16/17/27/20/21/37/38/30/31/34/35/54/48/49/52/53
VAR G4=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 51

STEREO ATTRIBUTES: NONE
L23 8285 SEA FILE=REGISTRY SUB=L17 SSS FUL L20

100.0% PROCESSED 13960 ITERATIONS 8285 ANSWERS
SEARCH TIME: 00.00.01

=> d que sta l30
L11 STR



VAR G1=O/S
REP G2=(1-3) C

VAR G3=7/9/11
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L13 SCR 1011 OR 1012 OR 1013 OR 1019
L15 SCR 1840
L17 17940 SEA FILE=REGISTRY SSS FUL L11 AND L13 AND L15
L20 STR







VAR G1=O/S
REP G2=(1-3) C
VAR G3=8/15/16/17/27/20/21/37/38/30/31/34/35/54/48/49/52/53
VAR G4=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 51

STEREO ATTRIBUTES: NONE
L23 8285 SEA FILE=REGISTRY SUB=L17 SSS FUL L20
L24 9655 SEA FILE=REGISTRY ABB=ON PLU=ON L17 NOT L23
L25 STR



VAR G1=O/S

REP G2=(1-3) C
VAR G3=7-4 8-11/9-4 10-11/CB
REP G4=(0-3) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L26 STR



VAR G1=O/S
REP G2=(1-3) C
VAR G3=7-4 8-13/9-4 10-13/CB
REP G4=(0-3) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L30 13 SEA FILE=REGISTRY SUB=L24 SSS FUL (L25 OR L26)

100.0% PROCESSED 267 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

=> b hcap
FILE 'HCAPLUS' ENTERED AT 13:04:51 ON 04 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Apr 2008 VOL 148 ISS 15
FILE LAST UPDATED: 3 Apr 2008 (20080403/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitstr l45 tot

L45 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:31512 HCAPLUS
DN 142:190237
TI Novel Heterocyclic Trans Olefin Analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor
AU Grundt, Peter; Carlson, Erin E.; Cao, Jianjing; Bennett, Christina J.; McElveen, Elizabeth; Taylor, Michelle; Luedtke, Robert R.; Newman, Amy Hauck
CS Medicinal Chemistry Section National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD, 21224, USA
SO Journal of Medicinal Chemistry (2005), 48(3), 839-848
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 142:190237
AB Dopamine D3 receptor subtypes have been hypothesized to play a pivotal role in modulating the reinforcing and drug-seeking effects induced by cocaine. However, definitive pharmacol. investigations have been hampered by the lack of highly D3 receptor selective compds. that can be used in vivo. To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (9H-fluorene-2-carboxylic acid {4-[(2,3-dichlorophenyl)-piperazin-1-yl]-butyl}-amide, Ki (hD3) = 2.0 nM, Ki (hD2L) = 112 nM, D2/D3 selectivity ratio of 56) was chosen as a lead structure for chemical modification in an attempt to reduce its high lipophillicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity. A series of >30 novel analogs were synthesized, and their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected with either D2L, D3, or D4 human dopamine receptors using the high affinity, selective D2-like receptor antagonist 125I-IABN. Structural diversity in the aryl amide end of the mol. was found to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was optimized using a more rigid trans-butenyl linker between the aryl amide and the piperazine. Several analogs demonstrated superior D3 receptor binding affinities and selectivities as compared to the parent ligand. Compound 29 (N-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine-2-yl-benzamide) displayed the most promising pharmacol. profile (Ki (hD3) = 0.7 nM, Ki (hD2L) = 93.3 nM, D2/D3 selectivity ratio of 133). In addition, this ligand inhibited quinpirole stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO) cells, with an EC50 value of 3.0 nM. Compound 29 was a nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM). Moreover, a decrease in c log D value of .apprx.2 orders of magnitude was determined for this novel D3-receptor-preferring ligand, compared to 1. In summary, chemical modification of 1 has resulted in compds. with high affinity and selectivity for D3 receptors. The most promising candidate, compound 29, is currently being evaluated in animal models of cocaine abuse and will provide an important tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.
IT 675599-29-8P 675599-30-1P 675599-31-2P
675599-32-3P 675599-34-5P 675599-35-6P
675599-36-7P 675599-38-9P 675599-39-0P
675599-45-8P 675599-46-9P 675599-47-0P
675599-48-1P 675599-49-2P 675599-52-7P
675599-53-8P 675599-54-9P 675599-55-0P
675599-56-1P 675599-58-3P 675599-59-4P
675599-61-8P 675599-62-9P 675599-64-1P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamide derivs.: preparation and affinity for D3 receptor)
IT 675599-29-8P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamide derivs.: preparation and affinity for D3 receptor)
RN 675599-29-8 HCAPLUS

L45 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Benzamide, N-[(2E)-4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-2-butenyl]-2-fluoro-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L45 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:252605 HCAPLUS
DN 140:287411
TI Preparation of structurally rigid arylpiperazines as dopamine D3 receptor selective ligands
IN Newman, Amy; Grundt, Peter; Luedtke, Robert R.
PA United States Department of Health and Human Services, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004024878	A2	20040325	2003WO-US028895	20030915
WO--2004024878	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2498936	A1	20040325	2003CA-002498936	20030915
AU--2003267201	A1	20040430	2003AU-000267201	20030915
US-20060106030	A1	20060518	2005US-000527594	20051213
PRAI 2002US-004107715P	P	20020914		
2003WO-US028895	W	20030915		

OS MARPAT 140:287411
GI



I

AB Title compds. [I; A = CH:CH, C.tplbond.C, cyclohexylene; B = null, CH:CH; R1 = (substituted) Ph, heteroaryl; R2 = H, halo, alkoxy; R3 = H, halo], were prepared Thus, carbonyldiimidazole was stirred 1 h with 4-hydroxybenzoic acid in pyridine; 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enylamine (preparation given) in CHCl3 was added followed by stirring overnight to give 51% N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl}-4-hydroxybenzamide (PG01015). PG01015 bound to cloned human D3 receptors in HEK cells with 34-fold greater affinity than to D2 receptors.
IT 675599-27-6P 675599-28-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of structurally rigid arylpiperazines as dopamine D3 receptor selective ligands)
IT 675599-29-8 675599-30-1 675599-31-2
675599-32-3 675599-34-5 675599-35-6
675599-36-7 675599-38-9 675599-39-0
675599-41-4 675599-43-6 675599-45-8
675599-46-9 675599-47-0 675599-48-1
675599-49-2 675599-51-6 675599-52-7
675599-53-8 675599-54-9 675599-55-0
675599-56-1 675599-58-3 675599-59-4
675599-61-8 675599-62-9 675599-64-1
675599-65-2 675599-66-3 675599-67-4
675599-68-5 675599-69-6 675599-71-0
675599-72-1 675599-73-2 675599-74-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of structurally rigid arylpiperazines as dopamine D3 receptor selective ligands)

L45 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 675599-27-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of structurally rigid arylpiperazines as dopamine D3 receptor selective ligands)
RN 675599-27-6 HCAPLUS
CN Benzamide, N-[(2E)-4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-2-butenyl]-4-iodo-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 675599-26-5
CMF C21 H22 Cl2 I N3 O

Double bond geometry as shown.



CM 2

CRN 144-62-7
CMF C2 H2 O4

=> d bib abs hitstr l44 tot

L44 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:442759 HCAPLUS
DN 139:230723
TI N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl]arylcarboxamides as novel dopamine D3 receptor antagonists
AU Newman, Amy Hauck; Cao, Jianjing; Bennett, Christina J.; Robarge, Michael J.; Freeman, Rebekah A.; Luedtke, Robert R.
CS Medicinal Chemistry Section, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, 21224, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(13), 2179-2183
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:230723
AB The dopamine D3 receptor subtype has been targeted as a potential neurochem. modulator of the behavioral actions of psychomotor stimulants, such as cocaine. Previous synthetic studies provided structural requirements for high affinity binding to D3 receptors which included a 2,3-dichloro-phenylpiperazine linked to an arylamido function via a Bu chain. To reduce lipophilicity of these agents and further investigate optimal conformation, a second series of 15 novel ligands was designed that included heteroarom. substitution and unsatd. alkyl linkers. These compds. were synthesized and evaluated for binding at rat D3 and D2 receptors stably expressed in Sf9 cells. D3 binding affinities ranged from Ki = 0.6-1080 nM, with a broad range of D3/D2 selectivities (2-97). The discovery of potent, selective and bioavailable D3 receptor ligands will provide essential mol. probes to elucidate the role D3 receptors play in the psychomotor stimulant and reinforcing effects of cocaine.
IT 595584-53-5P 595584-55-7P 595584-57-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of [(dichlorophenyl)piperazinyl]but(en)(yn)yl]arylcarboxamides as novel dopamine D3 receptor antagonists)
RN 595584-53-5 HCAPLUS
CN 9H-Fluorene-4-carboxamide, N-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-2-butynyl]-, ethanedioate, hydrate (4:4:1) (9CI) (CA INDEX NAME)

CM 1

CRN 595584-52-4
CMF C28 H25 Cl2 N3 O



CM 2

CRN 7732-18-5
CMF H2 O

H_2O

L44 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CM 3

CRN 144-62-7
CMF C2 H2 O4

RN 595584-55-7 HCAPLUS
CN 9H-Fluorene-2-carboxamide, N-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-2-butynyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 595584-54-6
CMF C28 H25 Cl2 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 595584-57-9 HCAPLUS
CN Benzamide, N-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-2-butynyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 595584-56-8
CMF C21 H21 Cl2 N3 O



CM 2

CRN 144-62-7
CMF C2 H2 O4

L44 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:80954 HCAPLUS
DN 118:80954
TI Preparation of N-[4-[(hetero)aryl]piperazinoalkyl]benzisothiazole-3-carboxamides and analogs as antipsychotics
IN Hrib, Nicholas J.; Jurcak, John G.
PA Hoechst-Roussel Pharmaceuticals Inc., USA
SO U.S., 14 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US-----5143923	A	19920901	1991US-000693168	19910429
	CA-----2067404	A1	19921030	1992CA-002067404	19920408
	CA-----2067404	C	20030819		
	EP------511610	A1	19921104	1992EP-000107138	19920427
	EP------511610	B1	19960911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
	IL------101700	A	19951127	1992IL-000101700	19920427
	PL------168090	B1	19960131	1992PL-000294358	19920427
	PL------168870	B1	19960430	1992PL-000309056	19920427
	AT------142628	T	19960915	1992AT-000107138	19920427
	ES----2094843	T3	19970201	1992ES-000107138	19920427
	NO-----9201654	A	19921030	1992NO-000001654	19920428
	NO------180488	B	19970120		
	NO------180488	C	19970430		
	AU-----9215187	A	19921105	1992AU-000015187	19920428
	AU-----644054	B2	19931202		
	JP----05132472	A	19930528	1992JP-000108229	19920428
	RU-----2039057	C1	19950709	1992RU-005011480	19920428
	CZ------282764	B6	19971015	1992CZ-000001298	19920428
	KR------215345	B1	19990816	1992KR-000007140	19920428
	HU------62889	A2	19930628	1992HU-000001414	19920429
	HU------214032	B	19971229		
	US-----5225412	A	19930706	1992US-000899518	19920616
	US-----5143923	B1	19931102	1992US-090002891	19921116
PRAI	1991US-000693168	A	19910429		

OS MARPAT 118:80954
GI



I



II

AB Title compds. [I; A = alkylene, CHR4ZCHR4; R1 = H, alkyl; R2 = alkyl, (substituted) Ph, -PhCH2, -Bz, -pyrimidyl, -benzisoxazol-3-yl, etc.; W = N, CH; X = O, S; Y = H, alkyl, alkoxy, OH, halo, CF3; Z = CH:CH, C.tplbond.C; n = 1, 2] were prepared Thus, N-methyl-N-(4-bromobutyl)-1,2-benzisothiazole-3-carboxamide was condensed with 4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine to give title compound II, which had ED50 of 1.5 mg/kg i.p. against apomorphine-induced climbing in mice.
IT 145759-36-0P 145759-37-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antipsychotic)
RN 145759-36-0 HCAPLUS
CN 1,2-Benzisothiazole-3-carboxamide, N-[4-[4-(2-methoxyphenyl)-1-

L44 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
piperazinyl]-2-butynyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 145759-37-1 HCAPLUS
CN 1,2-Benzisothiazole-3-carboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-2-butenyl]-, dihydrochloride, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 13:05:46 ON 04 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 13:05:46 ON 04 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:05:46 ON 04 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l42 1
```

L42 ANSWER 1 OF 3 USPATFULL on STN

AN 2006:125295 USPATFULL
TI Structurally rigid dopamine d3 receptor selective ligands and process for making them
IN Newman, Amy, Phoenix, MD, UNITED STATES
Grundt, Peter, Baltimore, MD, UNITED STATES
Luedtke, Robert R., Fort Worth, TX, UNITED STATES
PA Gov't of the USA as represented by The Secretary of the Department of Health and Human Services, Rockville, MD, UNITED STATES, 20852 (U.S. corporation)
PI US-20060106030 A1 20060518
AI 2003US-000527594 A1 20030915 (10)
2003WO-US0028895 20030915
20051213 PCT 371 date
PRAI 2002US-000410715P 20020914 (60)
DT Utility
FS APPLICATION
LREP Birch, Stewart, Kolasch & Birch, LLP, 8110 Gatehouse Rd, Suite 500 East, P.O. Box 747, Falls Church, VA, 22040-0747, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans --CH.dbd.CH--, --C.dbd.C--, or cyclohexyl. B is cis or trans --CH.dbd.CH-- or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 675599-27-6P 675599-28-7P
(preparation of structurally rigid arylpiperazines as dopamine D3 receptor selective ligands)
IT 675599-29-8 675599-30-1 675599-31-2
675599-32-3 675599-34-5 675599-35-6
675599-36-7 675599-38-9 675599-39-0
675599-41-4 675599-43-6 675599-45-8
675599-46-9 675599-47-0 675599-48-1
675599-49-2 675599-51-6 675599-52-7
675599-53-8 675599-54-9 675599-55-0
675599-56-1 675599-58-3 675599-59-4
675599-61-8 675599-62-9 675599-64-1
675599-65-2 675599-66-3 675599-67-4
675599-68-5 675599-69-6 675599-71-0
675599-72-1 675599-73-2 675599-74-3
(preparation of structurally rigid arylpiperazines as dopamine D3 receptor selective ligands)
IT 675599-27-6P
(preparation of structurally rigid arylpiperazines as dopamine D3 receptor selective ligands)
RN 675599-27-6 USPATFULL
CN Benzamide, N-[(2E)-4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-2-butenyl]-4-iodo-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 675599-26-5
CMF C21 H22 Cl2 I N3 O

Double bond geometry as shown.

L42 ANSWER 1 OF 3 USPATFULL on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

```
=> d bib abs hitstr l42 2-3
```

L42 ANSWER 2 OF 3 USPATFULL on STN
AN 93:54726 USPATFULL
TI Benzoisothiazole-and benzisoxazole-3-carboxamides
IN Hrib, Nicholas J., Somerville, NJ, United States
Jurcak, John G., Union City, NJ, United States
PA Hoechst-Roussel Pharmaceuticals Incorporated, Somerville, NJ, United States (U.S. corporation)
PI US-----5225412 19930706
AI 1992US-000899518 19920616 (7)
RLI Division of Ser. No. 1991US-000693168, filed on 29 Apr 1991, now patented, Pat. No. US-----5143923
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia
LREP Wittekind, Raymond R.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1,24,26
DRWN No Drawings
LN.CNT 1189
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel benzisothiazole- and benzisoxazole-3-carboxamides, processes and intermediates for the preparation thereof, and methods of treating psychoses utilizing compounds and compositions thereof are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 145759-36-0P 145759-37-1P
(preparation of, as antipsychotic)
RN 145759-36-0 USPATFULL
CN 1,2-Benzisothiazole-3-carboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-2-butynyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 145759-37-1 USPATFULL
CN 1,2-Benzisothiazole-3-carboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-2-butenyl]-, dihydrochloride, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

L42 ANSWER 3 OF 3 USPATFULL on STN
AN 92:72477 USPATFULL
TI Benzoisothiazole- and benziosoxazole-3-carboxamides
IN Hrib, Nicholas J., Somerville, NJ, United States
Jurcak, John G., Union City, NJ, United States
PA Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States (U.S. corporation)
PI US-----5143923 19920901
AI 1991US-000693168 19910429 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia
LREP Wittekind, Raymond R.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1158
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel benzisothiazole- and benzisoxazole-3-carboxamides, processes and intermediates for the preparation thereof, and methods of treating psychoses utilizing compounds and compositions thereof are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 145759-36-0P 145759-37-1P
(preparation of, as antipsychotic)
RN 145759-36-0 USPATFULL
CN 1,2-Benzisothiazole-3-carboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-2-butynyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 145759-37-1 USPATFULL
CN 1,2-Benzisothiazole-3-carboxamide, N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-2-butenyl]-, dihydrochloride, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

```
=> d his

     (FILE 'HOME' ENTERED AT 10:36:06 ON 04 APR 2008)

     FILE 'HCAPLUS' ENTERED AT 10:36:17 ON 04 APR 2008
L1            1 US5143923/PN

     FILE 'REGISTRY' ENTERED AT 10:36:32 ON 04 APR 2008

     FILE 'HCAPLUS' ENTERED AT 10:36:32 ON 04 APR 2008
L2              TRA L1 1- RN :       79 TERMS

     FILE 'REGISTRY' ENTERED AT 10:36:32 ON 04 APR 2008
L3           79 SEA L2
L4           32 L3 AND NC2NC2/ES
L5           18 L4 AND NSC3-C6/ES

     FILE 'HCAPLUS' ENTERED AT 11:19:51 ON 04 APR 2008
L6            1 US20060106030/PN

     FILE 'REGISTRY' ENTERED AT 11:20:04 ON 04 APR 2008

     FILE 'HCAPLUS' ENTERED AT 11:20:04 ON 04 APR 2008
L7              TRA L6 1- RN :       46 TERMS

     FILE 'REGISTRY' ENTERED AT 11:20:04 ON 04 APR 2008
L8           46 SEA L7
L9           41 L8 AND NC2NC2/ES AND 46.150.18/RID
L10          14 L9 AND (NC5 OR NC2NC2-C6 OR OC4-C6 OR SC4-C6 OR C5-C6-C6)/ES
L11             STR
L12          12 L11
L13             SCR 1011 OR 1012 OR 1013 OR 1019
L14          46 L11 AND L13
L15             SCR 1840
L16          46 L11 AND L13 AND L15
L17       17940 L11 AND L13 AND L15 FULL
                SAV TEM J594C1GVI/A L17
L18             STR L11
L19          50 L13 SAM SUB=L17
L20             STR L18
L21          50 L20 SAM SUB=L17
L22          38 L17 AND L8
L23        8285 L20 FULL SUB=L17
L24        9655 L17 NOT L23
L25             STR L11
L26             STR L25
L27           1 (L25 OR L26) SAM SUB=L24
L28           1 L26 SAM SUB=L24
L29           0 L25 SAM SUB=L24
L30          13 (L25 OR L26) FULL SUB=L24
L31           3 L30 AND L8

     FILE 'HCAPLUS' ENTERED AT 12:55:10 ON 04 APR 2008
L32           3 L30
L33           2 L22

     FILE 'REGISTRY' ENTERED AT 12:59:51 ON 04 APR 2008
L34         110 C23H24CL2N4O
L35           0 L34 AND L17
L36          22 L34 AND NC2NC2/ES
L37           0 L36 AND NC4-C6/ES

     FILE 'HCAOLD' ENTERED AT 13:01:10 ON 04 APR 2008
L38           0 L22
L39           0 L30

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 13:01:53 ON 04 APR 2008
L40           1 L22
L41           3 L30
```

```
L42           3 L40-41

     FILE 'HCAPLUS' ENTERED AT 13:03:22 ON 04 APR 2008
L43           1 L32 AND L33
L44           2 L32 NOT L43
L45           2 L33,L43

=>
```